Literature DB >> 2025982

Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

R Hartley1, W I Forsythe, B McLain, P C Ng, M D Lucock.   

Abstract

Total plasma carbamazepine, carbamazepine-10,11-epoxide (CBZ-EP) and 10,11-dihydro-10,11-trans-dihydroxy-carbamazepine (CBZ-DIOL) concentrations were measured during a 24h period in 21 patients receiving carbamazepine monotherapy, in equally divided doses, every 12h. Interdose and diurnal variations in plasma concentrations of parent drug and metabolites were assessed. Carbamazepine and both metabolites showed significant differences in mean 4h post-dose plasma concentrations between day and night dosing (p less than 0.001). Significant linear correlations were obtained between carbamazepine dose and plasma concentrations of carbamazepine, CBZ-EP and CBZ-DIOL when sampling times were standardised (p less than 0.01). Comparisons of plasma concentrations of the parent compound with those of its 2 main metabolites revealed significant linear correlations in all cases (p less than 0.01). The effects of daily fluctuations in plasma concentrations of all 3 compounds on their relative concentrations (CBZ-EP:carbamazepine, CBZ-DIOL:carbamazepine and CBZ-DIOL:CBZ-EP) during the 24h period were also determined: the plasma concentration ratios CBZ-EP:carbamazepine and CBZ-DIOL:carbamazepine were significantly related to the dose of carbamazepine at fixed sampling times (p less than 0.05, with 1 exception). The large interdose and diurnal variation in plasma carbamazepine concentrations observed in this study (approximately 40% decrease from peak to trough) has important implications both clinically and in relation to therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025982     DOI: 10.2165/00003088-199120030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  30 in total

1.  Preliminary observations of serum carbamazepine concentration in epileptic patients.

Authors:  J J Cereghino; J C Meter; J T Brock; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1973-04       Impact factor: 9.910

2.  Saliva carbamazepine levels in children.

Authors:  G W Rylance; G M Butcher; T Moreland
Journal:  Br Med J       Date:  1977-12-03

3.  Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

Authors:  R Riva; F Albani; G Ambrosetto; M Contin; P Cortelli; E Perucca; A Baruzzi
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

4.  Effect of dose increments on serum carbamazepine concentration in epileptic patients.

Authors:  E Perucca; P Bittencourt; A Richens
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

5.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

6.  Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

Authors:  T Tomson
Journal:  Arch Neurol       Date:  1984-08

7.  Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy.

Authors:  M Eichelbaum; L Bertilsson; L Lund; L Palmér; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

8.  Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children.

Authors:  J W Paxton; M G Aman; J S Werry
Journal:  Epilepsia       Date:  1983-12       Impact factor: 5.864

9.  Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

Authors:  M J Brodie; G Forrest; W G Rapeport
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  Carbamazepine and its major metabolites in plasma: a summary of eight years of therapeutic drug monitoring.

Authors:  H K Hundt; A K Aucamp; F O Müller; M A Potgieter
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

View more
  2 in total

Review 1.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 2.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.